Edition:
India

Evotec SE (EVTG.DE)

EVTG.DE on Xetra

19.92EUR
15 Oct 2019
Change (% chg)

€-0.20 (-1.02%)
Prev Close
€20.12
Open
€20.20
Day's High
€20.28
Day's Low
€19.38
Volume
1,321,952
Avg. Vol
1,169,262
52-wk High
€27.29
52-wk Low
€15.44

Latest Key Developments (Source: Significant Developments)

Evotec And Celmatix Enter Into Collaboration
Wednesday, 9 Oct 2019 

Oct 9 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION.PARTNERSHIP TO DEVELOP PRE-CLINICAL PROGRAMMES IN PREVALENT BUT UNDERSERVED CONDITIONS AFFECTING WOMEN'S REPRODUCTIVE HEALTH, INCLUDING POLYCYSTIC OVARY SYNDROME ("PCOS"), ENDOMETRIOSIS, AND INFERTILITY.NO FINANCIAL TERMS OF THIS COLLABORATION WERE DISCLOSED.  Full Article

Evotec, Takeda Enter Collaboration Across Multiple Therapeutic Fields
Tuesday, 24 Sep 2019 

Sept 24 (Reuters) - Evotec Se ::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.  Full Article

Evotec: Positive Phase II Data For P2x3 Antagonist
Thursday, 25 Jul 2019 

July 25 (Reuters) - EVOTEC SE ::POSITIVE PHASE II DATA FOR P2X3 ANTAGONIST IN PATIENTS WITH REFRACTORY CHRONIC COUGH.UNDERLYING MOLECULE IS A P2X3 ANTAGONIST ORIGINATING FROM EVOTEC/BAYER MULTI-TARGET ALLIANCE.PRELIMINARY EVALUATION INDICATED THAT ALL PRIMARY ENDPOINTS HAVE BEEN MET AND THAT IN STUDY BAY1817080 WAS FOUND TO BE SAFE AND WELL TOLERATED.  Full Article

Evotec And Venture Capital Consortium Form Breakpoint Therapeutics GmbH
Monday, 8 Jul 2019 

July 8 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND VENTURE CAPITAL CONSORTIUM FORM 'BREAKPOINT THERAPEUTICS GMBH'.FORMATION OF BREAKPOINT THERAPEUTICS GMBH, A SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE PORTFOLIO.ANNOUNCED FORMATION OF BREAKPOINT THERAPEUTICS GMBH, A SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE.SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE ("DDR") PORTFOLIO.GOAL OF SPIN-OFF COMPANY IS TO ACCELERATE EARLY PROJECTS THROUGH DISCOVERY AND PRE-CLINICAL DEVELOPMENT.TO DELIVER FIRST IND-READY DRUG IN 2022.BREAKPOINT THERAPEUTICS' MISSION IS TO DEVELOP FIRST AND BEST-IN-CLASS ONCOLOGY DRUGS THAT INTERFERE WITH DNA REPAIR AND REPLICATION STRESS PATHWAYS TO FACILITATE CURE OF THERAPY-RESISTANT CANCERS.BREAKPOINT THERAPEUTICS WILL INITIALLY FOCUS ON ADVANCING MULTIPLE DRUG DISCOVERY PROGRAMMES INITIATED AT EVOTEC THAT ADDRESS HIGH UNMET MEDICAL NEEDS OF DIFFERENT PATIENT GROUPS.GOAL OF SPIN-OFF COMPANY IS TO ACCELERATE EARLY PROJECTS THROUGH DISCOVERY AND PRE-CLINICAL DEVELOPMENT AND EXPECT TO DELIVER FIRST IND-READY DRUG IN 2022.EARLY STAGE FUNDING AMOUNTING TO EUR 30 M WILL BE COVERED BY A RENOWNED INTERNATIONAL INVESTOR CONSORTIUM LED BY MEDICXI, A LIFE SCIENCES-FOCUSED INVESTMENT FIRM, TAIHO VENTURES, LLC ("TAIHO"), VENTURE CAPITAL ARM OF TAIHO PHARMACEUTICAL, AND EVOTEC.EVOTEC WILL HOLD BELOW 50% OF COMPANY AND CONSOLIDATE AT EQUITY ACCORDINGLY..  Full Article

Evotec Places First 250 Mln Euro Promissory Note
Wednesday, 26 Jun 2019 

June 26 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC SE PLACES FIRST SCHULDSCHEIN (PROMISSORY NOTE) WORTH EUR 250 M.PROCEEDS TO BE USED FOR GENERAL CORPORATE FINANCING INCLUDING FINANCING OF JUST.BIO ACQUISITION, EXPANSION, AND REFINANCING.STRONG PERFORMANCE AND OUTLOOK OF COMPANY APPEALS TO DEBT INVESTORS AND RESULTS IN SIGNIFICANT OVERSUBSCRIPTION OF ORDER BOOK AT HIGHLY ATTRACTIVE TERMS.  Full Article

Evotec Acquires Just Biotherapeutics For Consideration Of Up To $90 Million
Tuesday, 21 May 2019 

May 20 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC JUMP-STARTS BIOLOGICS WITH ACQUISITION OF JUST BIOTHERAPEUTICS.EVOTEC SE <<>> - DEAL ACCRETIVE TO EVOTEC'S REVENUE GROWTH.EVOTEC SE <<>> - CONSIDERATION OF UP TO $ 90 M (APPROX. EUR 81 M) INCLUDING POTENTIAL EARN-OUTS 2019 - 2022.EVOTEC SE <<>> - ACQUISITION OF 100% OF ISSUED AND OUTSTANDING EQUITY INTERESTS OF COMPANY WILL BE PAID IN CASH .EVOTEC SE <<>> - JUST.BIO WILL BE FINANCIALLY FULLY CONSOLIDATED UNDER EVOTEC GROUP .  Full Article

Evotec Pays Back 140 Mln Euro Bridge Loan
Thursday, 18 Apr 2019 

April 18 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC COMPLETES REPAYMENT OF EUR 140 M ACQUISITION LOAN.EVOTEC COMPLETES REPAYMENT OF EUR 140 M ACQUISITION LOAN.BRIDGE LOAN WAS DRAWN TO SECURE EVOTEC'S VALUE CHAIN EXPANSION BY SUCCESSFUL ACQUISITION OF APTUIT IN AUGUST 2017.  Full Article

Evotec And Indivumed Announce Strategic Drug Discovery Collaboration
Thursday, 11 Apr 2019 

April 11 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND INDIVUMED ANNOUNCE STRATEGIC DRUG DISCOVERY COLLABORATION ON PRECISION MEDICINE FOR COLORECTAL CANCER.DGAP-NEWS: EVOTEC AND INDIVUMED ANNOUNCE STRATEGIC DRUG DISCOVERY COLLABORATION ON PRECISION MEDICINE FOR COLORECTAL CANCER.COLLABORATION RUNS FOR AN INITIAL TERM OF TWO YEARS.GOAL OF COLLABORATION IS TO DELIVER HIGHLY EFFECTIVE AND DURABLE TREATMENTS WITH CLEAR STRATEGIES FOR CRC PATIENT STRATIFICATION.  Full Article

Evotec Sees Adjusted EBITDA Up 10 Pct In 2019
Thursday, 28 Mar 2019 

March 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AG FISCAL YEAR 2018 RESULTS: ACCELERATED GROWTH AND STRONG LONG-TERM OUTLOOK.42% INCREASE IN GROUP REVENUES, ADJUSTED GROUP EBITDA UP 67%.STRONG START AND OUTLOOK FOR FISCAL YEAR 2019.GROUP REVENUES UP 42% TO EUR 375.4 M.ADJUSTED GROUP EBITDA UP 67% TO EUR 95.5 M (2017: EUR 57.2 M).STRONG STRATEGIC LIQUIDITY POSITION OF EUR 149.4 M.GROUP REVENUES EXPECTED TO INCREASE BY APPROX. 10%.ADJUSTED GROUP EBITDA EXPECTED TO IMPROVE BY APPROX. 10%.WILL FOCUS ITS GUIDANCE AND REPORTING DURING COURSE OF 2019 ON "UNPARTNERED RESEARCH AND DEVELOPMENT" PART, ESTIMATED AT APPROX. EUR 30-40 M.CURRENTLY, EVOTEC DOES NOT PLAN AN DISTRIBUTION OF DIVIDENDS.  Full Article

Evotec: New Partnership With GARDP To Discover Antibiotics
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Evotec AG ::EVOTEC AND GARDP ANNOUNCE NEW PARTNERSHIP TO DISCOVER NOVEL ANTIBIOTICS.DISCOVERY EFFORTS WILL FOCUS ON WORLD HEALTH ORGANIZATION ("WHO") PRIORITY PATHOGENS.BY JOINING FORCES, EVOTEC AND GARDP WILL LEVERAGE THEIR CAPABILITIES AND NETWORKS TO ADDRESS DRUG-RESISTANT BACTERIAL INFECTIONS.  Full Article